NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS   RESOURCES  
Small Claims Guide   Class Actions   Lemon Laws   FAQ   Newsletters  
Share


Complain about a product or service

Automotive    Education    Employment    Electronics    Family    Finance    Health    Homeowners    Insurance    Pets    Shopping    Travel     Print This     Email This    



NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

FDA Wants Irritable Bowel Drug Shelved

Public Citizen Has Warned of Zelnorm's Dangers for Years





By Mark Huffman
ConsumerAffairs.com

April 1, 2007

Drug Safety

FDA Unveils Safe Medication Use Program
Bayer Hit With Suit Over Prostate Claims
Feds Seize Alleged Seizure-Inducing Drugs
Matrixx Failed to Give FDA 800 Zicam Complaints
Matrixx Initiatives Pulls Zicam Products
FDA Issues Warning About Zicam Cold Remedy
FDA Issues Warning About Clarcon Skin Products
FDA Requires Additional Warning For OTC Pain Relievers
NY Mandates Multi-Lingual Rx Labels, Counsel
Two Firms Stopped From Making Unapproved Drugs
Supreme Court Upholds Consumers' Right to Sue Drug Companies In State Court
Psoriasis Drug Linked To Three Deaths
Bayer Agrees to Correct Misleading Information about Yaz
FDA Urged to Ditch Darvon
FDA Warns of Skin Numbing Product Dangers
Bayer Pays $97 Million to Settle Kickback Charges
FDA Seizes More Contaminated Heparin
FDA Warns Bayer on "Illegal" Drugs
Feds Seize More Than $24 Million in Unapproved New Drugs
Consumers Increasingly Exposed to Counterfeit Drugs
FDA Wants Black Box Warning on Antibiotics
Public Citizen Sues FDA for Failure to Act on Darvon
FDA Probes Arthritis Drug Link To Cancer
FDA Wants New Labeling Rules To Protect Pregnant, Nursing Women
Anti-Smoking Drug Chantix Linked to Seizures, Heart Problems, Diabetes
Bayer Pulls Trasylol From Market
MIT Researchers Confirm Contamination in Heparin
Be Careful Using Over-the-Counter Creams, Ointments
Another Heparin Producer Announces a Recall
FDA Moves Closer To Setting Up Shop In China
Study Raises Concerns About Anemia Drugs
Congress Hears Warnings about FDA
China Connection in Heparin Problems?
Heparin Linked to Severe Allergic Reactions
Antibiotic Leads to Tendon Ruptures
Second Safety Warning on Fentanyl Skin Patch
Merck Recalls Children's Vaccines
Study: Avandia May Do More Harm than Good
Texas Sues Drug Manufacturer Blamed for West Coast Deaths
Bayer Withdraws Antibleeding Drug Trasylol
---
More drug safety news ...

The Food and Drug Administration has told Novartis Pharmaceuticals Corporation that it wants it to suspend marketing of Zelnorm, used to treat irritable bowel syndrome. The agency said it requested the voluntary action based on recent findings of an increased risk of serious heart problems associated with use of the drug.

But Public Citizen says there's nothing recent about and notes that in March 2001, it petitioned the agency not to approve Zelnorm because it was only marginally effective and posed serious safety concerns. Besides heart problems, risks included ovarian cysts and fainting spells.

"We noted in this petition that receptors with which this drug interacts exist not only in the intestinal tract ... but also in the heart," said Dr. Sidney Wolfe, M.D., director of Public Citizen's Health Research Group.

"We pointed out that cisapride, a gastrointestinal drug which also caused fainting and was taken off the market because of cardiac arrhythmias, also affected this same receptor in the heart," Wolfe said.

"Once again, the FDA has approved a drug with marginal effectiveness in the face of serious questions about its safety -- putting at risk the millions of people who have already used it," Wolfe said.

He noted that the FDA has only asked the company to withdraw the drug from the market despite "even clearer evidence of harm.

"This again raises questions about both the adequacy of the FDA's pre-approval review and post-marketing surveillance," Wolfe said..

Zelnorm was approved by the FDA in July 2002 for short-term treatment of women with irritable bowel syndrome whose primary symptom is constipation. It was subsequently approved in August 2004 for treatment of chronic constipation for men and women under age 65. Zelnorm is currently marketed in 55 countries.

There were 2.13 million prescriptions issued for Zelnorm in 2005 alone, making it one of the top 200 drugs in the U.S., according to Public Citizen.

FDA said it advises patients who are using Zelnorm to contact their health care providers to discuss treatment alternatives. Patients who are taking Zelnorm should seek emergency medical care if they experience severe chest pain, shortness of breath, dizziness, sudden onset of weakness or difficulty walking or talking, or other symptoms of a heart attack or stroke, the FDA said.

FDA said it had only recently become aware of the drug's hazards. Its statement did not make any mention of the agency's ignoring Public Citizen's petition six years ago.

"This decision reflects the FDA's commitment to continuously monitor approved drugs throughout their marketing life, and take action when we believe the risks exceed the benefits," said Dr. Douglas Throckmorton, Deputy Director for the Center for Drug Evaluation and Research. "Here, a potential risk of very serious harm to patients who have this non-life-threatening condition was recently identified, making this action necessary."

Throughout February and March 2007, Novartis reported to FDA the results of a new analysis of 29 short-term randomized, controlled clinical trials of Zelnorm. FDA has concluded, based on these data that for most patients the benefits of this drug no longer outweigh the risks, the agency said.

The analysis included more than 11,600 patients treated with Zelnorm and over 7000 patients treated with placebo. The data showed that the risk of serious cardiovascular adverse events (e.g., angina, heart attacks, and strokes) associated with use of Zelnorm is higher than with placebo treatment.

Thirteen Zelnorm-treated patients (or 0.1%) had confirmed cardiovascular ischemic events, and only 1 placebo-treated patient (or 0.01%) with an event.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share

Follow us on Twitter.

FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!





CONSUMER NEWS

SAFETY RECALLS

Back to the top |

Advertisement


Custom Search
AUTOMOTIVE
• Dealers
• Manufacturers
• Service
• Extended Warranties
• Lemon Laws
• Recalls
• Tires
• Transporters

FAMILY
• Aging
• Children, Parenting
• Recalls
• Dating
• Education
• Entertainment
• Pets
• Weddings
FINANCE
• Annuities
• Banks
• Credit Cards
• Debt Collection
• Debt Counseling
• Insurance
• Investing
• Loans
• Mortgages
• Payday Loans
• Student Loans
• Tax Prep

HEALTH
• Doctors
• Drugs, Pharmacies
• Health Clubs
• Hearing Care
• Hospitals
• Nursing Homes
• Nutrition, Diets
• Vision Care
• Weight Loss
HOUSE & HOME
• Appliances
• Cookware
• Furniture
• Home Improvements
• Lawn & Garden
• Movers
• Pools & Spas
• Realtors, Rental Agents
• Recalls
• Utilities

ELECTRONICS
• Cable TV/DBS
• Cameras
• Cell Phones
• Computers
• Home Electronics
• Internet Access
• Local Phone Service
• Long Distance
• VoIP
SHOPPING
• In-Home
• Online
• Retail Stores
• Sporting Goods
• Supermarkets
• Telemarketers

TRAVEL
• Airlines
• Bus Lines
• Car Rental
• Cruises
• Hotels
• Travel Agents
• Trains

RESOURCES
• Class Actions
• Complaint Form
• Small Claims Guide
• Lemon Laws
CONSUMER NEWS
• Latest News
• Automotive
• Telecom
• Financial
• Health
• Homeowners
• Scams
• Seniors
• Travel
• More ...

RECALLS
• Automotive
• Children's Products
• Drugs
• Food
• Household Products
• Sporting Goods

ABOUT US
• FAQ
• Privacy Policy
• Advertise With Us
• Newsroom
• Syndication
• Terms of Use

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.